Placebo to Prazosin — Competitive Intelligence Brief

Placebo to Prazosin (Placebo to Prazosin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Alpha-1 adrenergic receptor antagonist. Area: Cardiovascular; Urology; Psychiatry (off-label).

marketed Alpha-1 adrenergic receptor antagonist Alpha-1 adrenergic receptor Cardiovascular; Urology; Psychiatry (off-label) Small molecule

Target snapshot

Placebo to Prazosin (Placebo to Prazosin) — Brian J Lipworth. Prazosin is an alpha-1 adrenergic receptor antagonist that blocks norepinephrine signaling to reduce blood pressure and improve urinary symptoms.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Placebo to Prazosin TARGET	Placebo to Prazosin	Brian J Lipworth	marketed	Alpha-1 adrenergic receptor antagonist	Alpha-1 adrenergic receptor
Continuous infusion of Norepinephrine	Continuous infusion of Norepinephrine	Hassan II University	marketed	Catecholamine; sympathomimetic amine	Alpha-1 adrenergic receptor; Beta-1 adrenergic receptor
Doxazosin extended release	Doxazosin extended release	University of Arkansas	marketed	Alpha-1 adrenergic receptor antagonist	Alpha-1 adrenergic receptor
Midodrine Oral Tablet	Midodrine Oral Tablet	Institute of Liver and Biliary Sciences, India	marketed	Alpha-1 adrenergic agonist	Alpha-1 adrenergic receptor
Naproxen Sodium & Pseudoephedrine HCl	Naproxen Sodium & Pseudoephedrine HCl	Dr. Reddy's Laboratories Limited	marketed	NSAID + sympathomimetic decongestant combination	COX-1/COX-2 (naproxen); alpha-1 adrenergic receptor (pseudoephedrine)
cardiac output changes with "phenylephrine"	cardiac output changes with "phenylephrine"	University Tunis El Manar	marketed	Alpha-1 adrenergic agonist	Alpha-1 adrenergic receptor
Eye injection (Mydrane)	Eye injection (Mydrane)	Medical University of Graz	marketed	Ophthalmic combination agent (mydriatic + anesthetic)	Muscarinic acetylcholine receptors (tropicamide); alpha-1 adrenergic receptors (phenylephrine); sodium channels (lidocaine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Alpha-1 adrenergic receptor antagonist class)

1. Brian J Lipworth · 1 drug in this class
2. CHU de Quebec-Universite Laval · 1 drug in this class
3. Eli Lilly and Company · 1 drug in this class
4. Haffkine Bio-Pharmaceutical Corporation Ltd. · 1 drug in this class
5. Hospital Authority, Hong Kong · 1 drug in this class
6. Japan Heart Foundation · 1 drug in this class
7. Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · 1 drug in this class
8. San Francisco Veterans Affairs Medical Center · 1 drug in this class
9. Sanofi · 1 drug in this class
10. Shanghai Huilun Pharmaceutical Co., Ltd. · 1 drug in this class